Regulation of hepatic glucose production by Gq-coupled receptors: potential new targets for treatment of type 2 diabetes.

Jane Mitchell

DOI: https://doi.org/10.1210/en.2013-1713

IF: 5.051

2013-12-04

Endocrinology

Abstract:G protein coupled receptors (GPCRs) constitute the largest family of receptors in the human genome with more than 700 members divided into 5 subfamilies based on similarities of sequence (1). Most, but not all, GPCRs couple through a smaller family of heterotrimeric G proteins to an even smaller group of signaling systems. These include the well-characterized systems of adenylyl cyclase activated by Gs and inhibited by Gi to regulate intracellular cAMP levels, as well as phospholipase Cproteins activated by Gq/11 proteins to regulate intracellular inositol trisphosphate, diacylglycerol, and intracellular calcium levels. With few exceptions, cells express multiple GPCRs, and most GPCRs are expressed in more than one tissue, making for a complex array of responses to endogenous ligands that are not overly amenable to tissue-selective pharmacologic regulation. Pharmacologic approaches are therefore limited in their ability to inform about the specific functions of individual GPCRs or even individual signaling systems in specific cells in vivo. Genetic approaches using loss-of-function animal models have been extensively used to identify functions of individual GPCRs in both nonselective and tissue selective models (2–4). Nevertheless it would be helpful to more specifically assess the effect of activating a particular G protein-regulated signaling system rather than knocking it out. One approach to this question has been the use of so called “designer” GPCRs that do not respond to endogenous ligands but can be selectively stimulated with synthetic ligands. This approach was first introduced more than 20 years ago when a modified 2-adrenergic receptor that had significant reduction in catecholamine stimulation but response, albeit at low affinity, to foreign ligands was reported (5). Later introduction of modified receptors such as Ro1, a modified Gi-coupled -opioid receptor, activated by synthetic ligands, have been useful tools (6– 8). The utility of these systems is limited by the selectivity of the synthetic ligand for the modified receptor; ideally there should be no binding to native receptors and no background biological activity. An improved synthetic ligand, clozapine-N-oxide (CNO) that has minimal biological activity but reasonable potency on modified muscarinic acetylcholine receptors was developed in 2007 (9). The article by Li et al. (10) in this issue of Endocrinology reports the generation of a transgenic mouse line (Hep-Rq) selectively expressing a modified Gq-coupled muscarinic M3 receptor, Rq (11) in liver. Importantly, the mice express levels of Rq comparable to other endogenous GPCRs. They used the mice to determine what role Gqcoupled GPCRs might play in regulation of blood glucose. Between meals, glucagon regulation of hepatic glucose production (HGP) maintains blood glucose levels. Glucagon acts through its Gs-coupled receptor in liver to stimulate gluconeogenesis and glycogenolysis. The effect of hepatic Gq-coupled receptors in regulation of blood glucose is less understood. Fasting hyperglycemia in type 2 diabetes is a significant clinical issue and is one of the targets of biguanides, such as metformin, a mainstay of antidiabetic therapy (12). Thus, further understanding of the role of hepatic Gq-coupled receptors could reveal new targets for therapy. Li et al. show that the synthetic ligand CNO increases blood glucose in fasted Hep-Rq mice in a dose-dependent manner with no effect in wild-type mice. Serum insulin response after glucose injection and blood glucose re-